To Compare the Effect of a Subcutaneous Canakinumab Administration to Placebo in Patients With Impaired Glucose Tolerance or Patients With Type 2 Diabetes With Differing Baseline Diabetes Therapies
Completed
Novartis
Phase 2
2010-02-01
This was a 10-week, placebo-controlled, randomized study to investigate the effect of
injectable IL-1B antagonist, Canakinumab , in participants with impaired glucose tolerance or
Type 2 Diabetes Mellitus (T2DM) already treated on different background diabetes therapies.
Effect of Pexidartinib on the Way the Body Processes CYP3A4 and CYP2C9 Substrates (Pharmacokinetics)
Completed
Daiichi Sankyo, Inc.
Phase 1
2018-02-26
This study has two parts.
Part 1 will evaluate how pexidartinib affects the way the body processes CYP3A4 and CYP2C9
substrates using midazolam and tolbutamide, respectively, as probe agents.
Part 2 will test the efficacy and safety of pexidartinib treatment in various tumor types.
In Part 2, the same participants will continue to receive pexidartinib twice daily.
Participants will be allowed to continue using pexidartinib as long as the participant
derives benefit.
Study in Healthy Subjects to Determine the Effect of Relacorilant on Exposure to Probe Substrates for Cytochrome P450s
Completed
Corcept Therapeutics
Phase 1
2018-03-06
This is an open-label, single-sequence, 3-period crossover study conducted in healthy
subjects. Eligible subjects will participate in a single treatment period, in which they will
receive the following treatments: Day 1, single doses of midazolam and metoprolol; Day 2,
single doses of pioglitazone, tolbutamide, and omeprazole; Days 5 to 17, daily doses of
relacorilant; Day 14, single doses of midazolam and metoprolol (with relacorilant); and, Day
15, single doses of pioglitazone, tolbutamide, and omeprazole (with relacorilant).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
